Catalog No.
RHA09401
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IF: 1:50-1:200, WB: 1:1000-1:2000
Target
p110delta, PIK3CD, PtdIns-3-kinase subunit p110-delta, PI3Kdelta, PI3K-delta, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, PI3-kinase subunit delta, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, PtdIns-3-kinase subunit delta
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O00329
Applications
IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1C83
The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity., PMID:40294837
The Burden of Non-Infectious Organ-Specific Immunopathology in Pediatric Common Variable Immunodeficiency., PMID:40141295
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls., PMID:40114918
Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques., PMID:39950029
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance., PMID:39745891
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
Clinical features and lymphocyte immunophenotyping analysis in primary immunodeficiency patients with non-transplant lymphoproliferative disorders., PMID:38838929
B-cells absence in patients diagnosed as inborn errors of immunity: a registry-based study., PMID:38683392
Phenotypic and Immunological Characterization of Patients with Activated PI3Kδ Syndrome 1 Presenting with Autoimmunity., PMID:38634985
Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype., PMID:38287413
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
Inborn errors of human B cell development, differentiation, and function., PMID:37273190
Clinical Features and Genetic Analysis of Taiwanese Primary Immunodeficiency Patients with Prolonged Diarrhea and Monogenetic Inflammatory Bowel Disease., PMID:37202577
Activated PI3Kδ syndrome 1 mimicking systemic lupus erythematosus and secondary Sjögren's syndrome-like phenotype without recurrent infections: A case report., PMID:36605759
When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders., PMID:36209991
Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene., PMID:35799777
Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study., PMID:34975878
PI3Kδ inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation., PMID:34920698
Activated PI3Kδ signals compromise plasma cell survival via limiting autophagy and increasing ER stress., PMID:34586341
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management., PMID:34447369
Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes., PMID:34422726
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence., PMID:34350147
The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome., PMID:34214886
Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report., PMID:34039074
Case Report: Activating PIK3CD Mutation in Patients Presenting With Granulomatosis With Polyangiitis., PMID:33995405
PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation., PMID:33681239
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient., PMID:33506299
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3., PMID:33093155
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome., PMID:32961022
Effects of AS2819899, a novel selective PI3Kδ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model., PMID:32736191
Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation., PMID:32443356
Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency., PMID:32349894
Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus., PMID:34522717
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study., PMID:31964785
Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production., PMID:31841125
Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes., PMID:31786159
(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ., PMID:31691624
Treatment of pemphigus vulgaris: part 2 - emerging therapies., PMID:31575295
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia., PMID:31490009
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia., PMID:31137964
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report., PMID:31045771
Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies., PMID:30891027
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines., PMID:30819916
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature., PMID:30799802
Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor., PMID:30755348
Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells., PMID:30738173
PI3K Orchestrates T Follicular Helper Cell Differentiation in a Context Dependent Manner: Implications for Autoimmunity., PMID:30666254
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia., PMID:30573773
Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome., PMID:30499059
Phosphoinositide 3-kinase-delta could be a biomarker for eosinophilic nasal polyps., PMID:30375439
For research use only. Not for human or drug use.
